Clinical Trial Update: Radium-223 in Combination With Enzalutamide [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Radium-223 in combination with enzalutamide for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)
• Xtandi (enzalutamide)

Snippet

Sponsor: Cancer Trials Ireland | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED